HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)

The investigators propose redefining this concept by focusing on volume rather than the number of metastases. To achieve this, the investigators aim to determine the Maximum Tolerated Volume (MTV) of metastatic lesions treatable with SRT (Stereotaxic radiotherapy) in a phase 1 study. In this study, the investigators will recruit patients with high-volume metastatic disease in bones or lymph nodes and progressively irradiate a volume-escalated subset of the total lesions. The selection will prioritize lesions at higher risk of causing pain or complications, such as fractures, spinal compression

Trial Details

NCT ID
NCT06978296
Phase
NA
Sponsor
Institut Cancerologie de l'Ouest
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Stereotactic body radiotherapy (SBRT)
Locations (sample)
  • Saint-Herblain, France|47.21154,-1.651

Key Eligibility Criteria

  • Metastatic prostate cancer with clinical progression after the use of androgen-receptor pathway inhibitor, chemotherapy or any other life-prolongin…
  • Performance Status \< 3
  • Bone and/or lymph node metastases based on conventional (CT and bone scan) or metabolic imaging
  • Bone and/or lymph node metastases suitable for SRT, according to the investigator

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →